Alembic Pharma Net profit rises 25 percent to Rs 293 crore in Q3

"It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in the current quarter," Alembic Pharmaceuticals Managing Director Pranav Amin said.

Published On 2021-01-21 03:45 GMT   |   Update On 2021-01-21 03:45 GMT

New Delhi: Drug firm Alembic Pharmaceuticals on Tuesday reported a 24.92 percent rise in its consolidated net profit to Rs 292.57 crore for the December quarter mainly on account of robust sales. The company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals said in a regulatory filing.The consolidated revenue...

Login or Register to read the full article

New Delhi: Drug firm Alembic Pharmaceuticals on Tuesday reported a 24.92 percent rise in its consolidated net profit to Rs 292.57 crore for the December quarter mainly on account of robust sales.

The company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals said in a regulatory filing.

The consolidated revenue from operations of the company stood at Rs 1,314.33 crore for the quarter under consideration. It was Rs 1,209.13 crore for the same period a year ago, it added.
"It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in the current quarter," Alembic Pharmaceuticals Managing Director Pranav Amin said.
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News